| abstract |
The present invention relates to a molecule comprising a mutant Fc region, in particular a polypeptide, and more particularly to an immunoglobulin (eg, an antibody), wherein the mutant Fc region is modified by at least one amino acid relative to the wild type Fc region. And binds to FcγRIIIA and / or FcγRIIA with higher affinity than the corresponding molecule containing the wild-type Fc region. The molecules of the invention are particularly useful for preventing, treating or ameliorating one or more symptoms associated with a disease, disorder or infection. The molecules of the invention may also be used to treat or prevent diseases or disorders where increased efficacy of FcγR-mediated effector cell function (eg, ADCC) is desired (eg, cancer, infection), and therapeutic antibodies It is particularly useful to enhance the therapeutic efficacy of (its effect is mediated by ADCC). |